News

Skin cancer treatment costs skyrocket over past decade


 

FROM THE AMERICAN JOURNAL OF PREVENTIVE MEDICINE

References

The average annual cost for skin cancer treatment more than doubled from 2002 to 2011, a report from the Centers for Disease Control and Prevention found.

From 2002 to 2006, the average annual skin cancer treatment cost was $3.6 billion, while for 2007-2011, the average annual cost was $8.1 billion, an increase of about 126%. The cost of nonmelanoma skin cancers increased 74%, from $2.7 billion to $4.8 billion, but the average annual cost for melanoma cancers increased about 280%, from $864 million to $3.3 billion, according to the CDC (Am. J. Prev. Med. 2014 Nov. 9 [doi:10.1016/j.amepre.2014.08.036]).

From 2002 to 2006, the average annual number of adults treated for skin cancer was 3.4 million, which increased to an average annual number of 4.9 million for 2007-2011. The average annual cost per person for all skin cancers increased by 57%, from $1,044 for 2002-2006 to $1,643 for 2007-2011, while the average cost for melanomas more than doubled from $2,320 to $4,780. The increase in annual cost for nonmelanoma skin cancers was more modest; only a 25% increase, from $882 to $1,105, was noted between the two time periods, the CDC reported.

The average annual cost for all cancer treatment rose from $67.3 billion for 2002-2006 to $87.8 billion for 2007-2011, an increase of $20.5 billion. While skin cancer treatment costs represented only 5% of all treatment costs in 2002-2006, the increase in skin cancer costs was 22% of the total increase, so from 2007 to 2011, skin cancer represented 9% of all treatment costs, according to data from the Medical Expenditure Panel Survey.

lfranki@frontlinemedcom.com

Recommended Reading

VIDEO: MEK/BRAF combo puts brakes on BRAF-mutated advanced melanoma progression
MDedge Dermatology
Spontaneously Regressing Primary Nodular Melanoma of the Glans Penis
MDedge Dermatology
VIDEO: A new system for staging squamous cell carcinoma
MDedge Dermatology
Investigational nivolumab beats chemo in pretreated advanced melanoma
MDedge Dermatology
COMBI-v affirms combination MEK, BRAF blockade in melanoma
MDedge Dermatology
Nine weeks of biochemotherapy effective for high-risk melanoma
MDedge Dermatology
Sargramostim addition improves survival in metastatic melanoma
MDedge Dermatology
Tumor Volume: An Adjunct Prognostic Factor in Cutaneous Melanoma
MDedge Dermatology
Risk Factors for Malignant Melanoma and Preventive Methods
MDedge Dermatology
Health-Related Quality of Life in Skin Cancer Patients
MDedge Dermatology